摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Methyl-3-[2-(4-ethylbenzyloxy)ethoxy]7-ethoxycarbonylmethylthio-pyrazolo[4,3-d]pyrimidine | 100566-18-5

中文名称
——
中文别名
——
英文名称
2-Methyl-3-[2-(4-ethylbenzyloxy)ethoxy]7-ethoxycarbonylmethylthio-pyrazolo[4,3-d]pyrimidine
英文别名
Ethyl 2-[3-[2-[(4-ethylphenyl)methoxy]ethoxy]-2-methylpyrazolo[4,3-d]pyrimidin-7-yl]sulfanylacetate
2-Methyl-3-[2-(4-ethylbenzyloxy)ethoxy]7-ethoxycarbonylmethylthio-pyrazolo[4,3-d]pyrimidine化学式
CAS
100566-18-5
化学式
C21H26N4O4S
mdl
——
分子量
430.528
InChiKey
QDRVJBGDJBRVIO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    30
  • 可旋转键数:
    12
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    114
  • 氢给体数:
    0
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Pyrazolo[4,3-d]pyrimidine derivative, process for its production,
    申请人:Nissan Chemical Industries Ltd.
    公开号:US04654348A1
    公开(公告)日:1987-03-31
    A pyrazolo[4,3-d]pyrimidine derivative having the formula: ##STR1## wherein R.sup.1 is lower alkyl or phenyl, R.sup.2 is --A--CO.sub.2 R.sup.21 (wherein A is alkylene having from 1 to 10 carbon atoms which is unsubstituted or substituted by alkyl having from 1 to 3 carbon atoms; and R.sup.21 is lower alkyl having from 1 to 4 carbon atoms), --CH.sub.2 CO-phenyl, a saturated or unsaturated, straight chain or branched aliphatic group having from 3 to 16 carbon atoms, phenyl-lower alkyl, --CH.sub.2 CN, chloro substituted phenyl-lower alkyl or ##STR2## (wherein R.sup.22 is hydrogen or lower alkyl), and R.sup.3 is a saturated or unsaturated, straight chain or branched aliphatic group having from 2 to 22 carbon atoms, phenyl-lower alkyl, benzyloxy substituted phenyl-lower alkyl, lower alkyl substituted or unsubstituted 2-(phenylmethyloxy)ethyl, cyclohexylcyclohexyl, methylcyclohexyl, 3-thia-n-heptyl, 3,6-dioxa-n-decyl, 4-oxo-n-pentyl or 2-hydroxyethyl. Intermediates and processes of making the compounds of formula I are also disclosed. The compounds of formula I are useful as antihyperlipidemic agents.
    一种具有以下结构的吡唑并[4,3-d]嘧啶生物:##STR1##其中R.sup.1是较低的烷基或苯基,R.sup.2是--A--CO.sub.2R.sup.21(其中A是具有1至10个碳原子的未取代或取代的烷基,取代基为具有1至3个碳原子的烷基;R.sup.21是具有1至4个碳原子的较低烷基),--CH.sub.2CO-苯基,具有3至16个碳原子的饱和或不饱和、直链或支链脂肪族基团,苯基-较低烷基,--CH.sub.2CN,取代的苯基-较低烷基或##STR2##(其中R.sup.22是氢或较低烷基),R.sup.3是具有2至22个碳原子的饱和或不饱和、直链或支链脂肪族基团,苯基-较低烷基,苄氧基取代的苯基-较低烷基,取代或未取代的2-(苯基甲氧基)乙基,环己基环己基,甲基环己基,3-代-n-庚基,3,6-二氧-n-癸基,4-氧代-n-戊基或2-羟乙基。还公开了制备式I化合物的中间体和工艺。式I化合物可用作抗高脂血症药物。
  • Pyrazolo[4,3-d] pyrimidine derivative process for its production antihyperlipidemic agent containing it, its intermediate, and process for the production of the intermediate
    申请人:NISSAN CHEMICAL INDUSTRIES LTD.
    公开号:EP0157415A2
    公开(公告)日:1985-10-09
    A pyrazolo[4,3-d]pyrimidine derivative having the formula: wherein R1 is lower alkyl, phenyl or substituted phenyl, R2 is -A-CO2R21 (wherein A is alkylene having from 1 to 3 carbon atoms which is unsubstituted or substituted by methyl, and R21 is lower alkyl having from 1 to 4 carbon atoms), -CH2CO-phenyl, a saturated or unsaturated, straight chain or branched aliphatic group having from 3 to 16 carbon atoms, phenyl-lower alkyl, -CH2CN, substituted phenyl-lower alkyl, cyclohexylcyclohexyl, methylcyclohexyl, 4-thia-n-heptyl, 3,6-dioxa-n-octyl, 4-oxo-n-pentyl or (wherein R22 is hydrogen or lower alkyl), and R3 is a saturated or unsaturated, straight chain or branched aliphatic group having from 2 to 22 carbon atoms, phenyl-lower alkyl, substituted phenyl-lower alkyl, substituted or unsubstituted phenyl-methyloxyethyl or 2-hydroxyethyl.
    一种吡唑并[4,3-d]嘧啶生物,其式如下 其中 R1 是低级烷基、苯基或取代苯基,R2 是-A-CO2R21(其中 A 是具有 1 至 3 个碳原子的亚烷基,未被取代或被甲基取代,R21 是具有 1 至 4 个碳原子的低级烷基),-CH2CO-苯基、具有 3 至 16 个碳原子的饱和或不饱和、直链或支链脂肪族基团、苯基低级烷基、-CH2CN、取代苯基低级烷基、环己基环己基、甲基环己基、4-杂-n-庚基、3,6-二氧杂-n-辛基、4-氧代-n-戊基,或 (其中 R22 为氢或低级烷基),R3 为具有 2 至 22 个碳原子的饱和或不饱和、直链或支链脂族基团、苯基-低级烷基、取代的苯基-低级烷基、取代或未取代的苯基-甲基羟乙基或 2-羟乙基。
  • FUJIKAWA, YOSHIHIRO;SUZUKI, MIKIO;SAKASHITA, MITSUAKI;TSURUZOE, NOBUTOMO;+
    作者:FUJIKAWA, YOSHIHIRO、SUZUKI, MIKIO、SAKASHITA, MITSUAKI、TSURUZOE, NOBUTOMO、+
    DOI:——
    日期:——
  • US4654348A
    申请人:——
    公开号:US4654348A
    公开(公告)日:1987-03-31
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)